Genomind Clinical Study Demonstrates effectiveness of the Genecept™ Assay

Genomind Clinical Study Demonstrates effectiveness of the Genecept™ Assay

American Journal of Managed Care publishes results displaying increased medication adherence and lower healthcare costs in response to genetic testing.

CHALFONT, PA – June 3, 2014 – Genomind, a personalized medicine company, is pleased to announce the publication of its clinical study, “Pharmacogenetic-Guided Psychiatric Intervention Associated with Increased Adherence and Cost Savings”, in the American Journal of Managed Care (AJMC) (May, 2014).

This study, undertaken with IMS Health, demonstrated a cost savings of 9.5% in outpatient costs over the four month trial period for patients who utilized the Assay compared to patients who did not. This equates to a relative annual outpatient cost savings of $1,686 per patient. Additionally, patients who used the Genecept Assay had significantly increased medication adherence rates when compared to matched controls.

“This is the first published study examining the Genecept Assay and its impact on resource utilization and medication adherence,” said Dr. Jay Lombard, Genomind’s Chief Scientific Officer and Medical Director. “This study provides real-world evidence that the Genecept Assay leads to increased medication adherence and lower healthcare costs.”

This adds to a growing body of evidence that pharmacogenetic testing can inform treatment interventions, leading to increased medication adherence in otherwise difficult to treat patients. The observed increase in adherence was associated with a significant decrease in overall costs related to outpatient activity. The study demonstrates that pharmacogenetic testing helps reduce the elevated healthcare costs of this population by identifying effective therapies and increasing medication adherence, thus decreasing the need for excess healthcare services.

About Genomind

Genomind is a personalized medicine company, comprised of innovative researchers and expert leaders in psychiatry and neurology. Genomind is committed to discovery of the underlying causes of neuropsychiatric disorders and supports the development of personalized medicine that improves patients’ lives. Genomind was founded by Ronald I. Dozoretz, MD, a psychiatrist who has devoted his career to improving mental health. Jay Lombard, DO, a neurologist and co-founder of Genomind, is a critically acclaimed author and nationally recognized thought leader in neuropsychiatry practice and research. Learn more at http://www.genomind.com.

About the Genecept Assay

The Genecept Assay is a comprehensive, simple-to-use tool for understanding genetic and biological markers that best inform response to different psychiatric treatments. The Assay is Genomind’s core product, and contains a proprietary panel of biomarker tests, an analytic report, and a psychopharmacologist consultation. The Assay can be used for a range of psychiatric conditions including depression, bipolar disorder, schizophrenia, anxiety disorders, OCD and ADHD. For more information on the Assay, including information about the specific genes in the panel, please visit http://www.genomind.com/how-it-works/.

About The American Journal of Managed Care (AJMC)

The American Journal of Managed Care is an independent, peer-reviewed publication dedicated to disseminating clinical information to managed care physicians, clinical decision-makers, and other healthcare professionals. Now in its 20th year, its aim is to stimulate scientific communication in the ever-evolving field of managed care. For more information, please visit http://www.ajmc.com.

For more information, contact:

Adam Shapiro
ASPR
202-427-3603
Adam.Shapiro@ASPR.bz

Amy Pressman
Marketing Manager, Genomind
267-532-8866
apressman@genomind.com